November 18, 2024

Apocrine Gland Changes in Early Hidradenitis Suppurativa

Conexiant

November 18, 2024

Renowned Dermatologist Goldsmith Dies at 86

"No one ever trades in a Rolls Royce—they just maintain the one they have," quipped pioneering dermatologist Lowell Goldsmith after cardiac surgery, exemplifying the wit and wisdom that marked his 57-year career advancing dermatologic medicine.

Conexiant

November 05, 2024

Catholic Hospitals Shift to Megacorporations as Nuns Vanish

Discover how the original mission of Catholic hospitals led by nuns has transformed into a question of identity and purpose in modern healthcare.

KFF Health News

October 29, 2024

Study: Parent Physicians Face $2M Pay Gap

Parent physicians face stark earning divides: mothers' pay drops with each child while fathers see raises, creating $2M career gap.

Conexiant

October 29, 2024

Plastics, Diet Linked to Hidradenitis Suppurativa

In a study of hidradenitis suppurativa, 82.35% of patients reported dietary changes as helpful in managing symptoms, while the condition showed significant correlations with processed food consumption, plastic container use, and sweating patterns (P<0.05).

Conexiant

May 10, 2024

Adalimumab: A Blood Booster for HS Patients?

Adalimumab improves hematologic markers in hidradenitis suppurativa patients, regardless of clinical response.

Conexiant

October 11, 2024

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.

Conexiant

June 05, 2024

Noncompete Ban May Not Help Nonprofit Workers

Health care professionals welcome the FTC's new rule banning noncompete agreements but are concerned it may not protect those in nonprofit health care settings, potentially impacting most of the nation's medical professionals.

KFF Health News

July 23, 2024

Drug Industry Middlemen Defend Model at Congressional Hearing

They attributed the high costs to "patent abuses" by drug manufacturers, which delay the launch of cheaper generic and biosimilar medicines.

Reuters